Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bertz

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Clinical Pharmacology and Therapeutics|February 12, 2015
Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 proteaseT Eley, Y-H Han, S-P Huang, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2016
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529Ishani Landry, Li Zhu, Malaz Abu Tarif, et al.
Journal of Clinical Pharmacology|July 20, 2016
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy SubjectsLi Zhu, Roger J Brüggemann, Jonathan Uy, et al.
Pharmaceutical Research|August 16, 2002
Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431Franklin W Okumu, Rai-Yun Lee, James D Blanchard, et al.
Journal of Cancer Research and Clinical Oncology|September 16, 2023
Introducing a standardized assessment of patients' interest in and usage of CAM in routine cancer care: chances and risks from patients' and physicians' point of viewM Shalgouny, J Bertz-Lepel, L Fischer V Weikersthal, et al.
The Pediatric Infectious Disease Journal|March 14, 2003
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenXavier Sáez-Llorens, Avyi Violari, Carl O Deetz, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Clinical Pharmacology and Therapeutics|February 12, 2015
Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 proteaseT Eley, Y-H Han, S-P Huang, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2016
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529Ishani Landry, Li Zhu, Malaz Abu Tarif, et al.
Journal of Clinical Pharmacology|July 20, 2016
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy SubjectsLi Zhu, Roger J Brüggemann, Jonathan Uy, et al.
Pharmaceutical Research|August 16, 2002
Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431Franklin W Okumu, Rai-Yun Lee, James D Blanchard, et al.
Journal of Cancer Research and Clinical Oncology|September 16, 2023
Introducing a standardized assessment of patients' interest in and usage of CAM in routine cancer care: chances and risks from patients' and physicians' point of viewM Shalgouny, J Bertz-Lepel, L Fischer V Weikersthal, et al.
The Pediatric Infectious Disease Journal|March 14, 2003
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenXavier Sáez-Llorens, Avyi Violari, Carl O Deetz, et al.
Pageof 6